LAF237 is the lead DPP-IV inhibitor compound from Novartis.

Preliminary results of 12 week Phase 2 studies show LAF237 was well tolerated and demonstrated surprising glucose-lowering potency both as monotherapy, and in combination with metformin. Novartis is proceeding to Phase 3 Clinical Trials with this compound. See this weeks Item #2. To get slides on how LAF237 works

click here